دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Cover Image
Grit Andersen MD, Rosy Eloy MD, Susanne Famulla PhD, Tim Heise MD, Grégory Meiffren PhD, Cyril Seroussi MSc, Martin Gaudier PhD, Claire Mégret PhD, You-Ping Chan PhD, Olivier Soula PhD, Matthew Riddle MD,Â
doi : 10.1111/dom.15067
Volume 25, Issue 5
Alleviation of functional iron deficiency by SGLT2 inhibition in patients with type 2 diabetes
Milton Packer MD,Â
doi : 10.1111/dom.14963
The role of dietary salt in metabolism and energy balance: Insights beyond cardiovascular disease
Qi Wu, George Burley, Li-Cheng Li, Shu Lin, Yan-Chuan Shi,Â
doi : 10.1111/dom.14980
Dietary salt (NaCl) is essential to an organism's survival. However, today's diets are dominated by excessive salt intake, which significantly impacts individual and population health. High salt intake is closely linked to cardiovascular disease (CVD), especially hypertension, through a number of well-studied mechanisms. Emerging evidence indicates that salt overconsumption may also be associated with metabolic disorders.
Detecting and treating the protean manifestations of diabetic autonomic neuropathy
David S. H. Bell MB,
doi : 10.1111/dom.15004
The manifestations of diabetic autonomic neuropathy (DAN) are protean and clinically involve multiple systems, including the cardiovascular system, the gastrointestinal system, the genitourinary system as well as the sweat glands (sudomotor dysfunction) and the gallbladder.
Anagliptin twice-daily regimen improves glycaemic variability in subjects with type 2 diabetes: A double-blind, randomized controlled trial
Yong-ho Lee MD, Doo-Man Kim MD, Jae Myung Yu MD, Kyung Mook Choi MD, Sin Gon Kim MD, Kang Seo Park MD, Hyun-Shik Son MD, Choon Hee Chung MD, Kyu Jeung Ahn MD, Soon Hee Lee MD, Ki-Ho Song MD, Su Kyoung Kwon MD, Hyeong Kyu Park MD, Kyu Chang Won MD, Hak Chul Jang MD, on behalf of the ACACIA Study Group ,Â
doi : 10.1111/dom.14959
To determine whether the twice-daily (BID) regimen is superior to the once-daily (QD) regimen for managing glycaemic variability by comparing the effects of anagliptin 100 mg BID versus sitagliptin 100 mg QD.
Exercise-related hypoglycaemia induces QTc-interval prolongation in individuals with type 1 diabetes
Per G. Hagelqvist MD, Andreas Andersen PhD, Kaisar B. Maytham BSc, Christine R. Andreasen MD, Susanne Engberg PhD, Tommi B. Lindhardt PhD, Jens Faber DMSc, Jens J. Holst DMSc, Julie L. Forman PhD, Ulrik Pedersen-Bjergaard DMSc, Filip K. Knop PhD, Tina Vilsbøll DMSc,Â
doi : 10.1111/dom.14964
To investigate changes in cardiac repolarisation during exercise-related hypoglycaemia compared to hypoglycaemia induced at rest in people with type 1 diabetes.
Lifestyle intervention for the prevention of type 2 diabetes in women with prior gestational diabetes: A systematic review and meta-analysis
Matthew Retnakaran, Luciana V. Viana MD, Caroline K. Kramer MD,Â
doi : 10.1111/dom.14966
To determine whether current evidence supports lifestyle intervention for type 2 diabetes (T2D) prevention in women with previous gestational diabetes (GD).
A microbiome-targeting fibre-enriched nutritional formula is well tolerated and improves quality of life and haemoglobin A1c in type 2 diabetes: A double-blind, randomized, placebo-controlled trial
Juan P. Frias MD, Martin L. Lee PhD, Matthew M. Carter, Emily R. Ebel PhD, Ren-Hau Lai PhD, Lars Rikse, Marc E. Washington MBA, Justin L. Sonnenburg PhD, Christopher J. Damman MD,Â
doi : 10.1111/dom.14967
To investigate a prebiotic fibre-enriched nutritional formula on health-related quality of life and metabolic control in type 2 diabetes.
Liver-expressed antimicrobial peptide 2 is associated with improved pancreatic insulin secretion in adults with overweight and obesity
Romana Stark PhD, Jack Feehan PhD, Aya Mousa PhD, Zane B. Andrews PhD, Barbora de Courten PhD,Â
doi : 10.1111/dom.14968
To examine association of liver-expressed antimicrobial peptide 2 (LEAP2), an endogenous ghrelin antagonist with anorexiant effects, to key cardiometabolic risk factors in people with overweight and obesity.
Efficacy and safety of basal-first titration order in individuals with type 2 diabetes receiving short-term intensive insulin therapy: An exploratory analysis of BEYOND V
Yijun Li MD, Dongni Yu MMed, Lixin Guo MD, Yiming Mu PhD, Hailong Wan BMed, Junfen Wang BMed, Binhua Xu MMed, Guoping Wang MMed, Chengxia Jiang BMed, Li Liang BMed, Jiewen Zhang PhD, Jingcheng Liu PhD, Minlu Zhang MPH, Nan Cui MD,Â
doi : 10.1111/dom.14970
To present the results of an exploratory analysis of the BEYOND V study in which Chinese individuals with uncontrolled type 2 diabetes (T2D) received short-term intensive insulin therapy (SIIT) during study run-in (prior to randomization) using a basal-first insulin titration method.
Efficacy and safety of janagliflozin monotherapy in Chinese patients with type 2 diabetes mellitus inadequately controlled on diet and exercise: A multicentre, randomized, double-blind, placebo-controlled, Phase 3 trial
Linong Ji MD, Xiaozhen Jiang MB, Qingshun Hao MB, Zhifeng Cheng MD, Kun Wang MD, Shuguang Pang MD, Meiying Liu MM, Yushan Guo MM, Xiaowen Chen MM, Xiuhai Su MB, Tao Ning MB, Jie Liu MM, Fang Bian MB, Yulan Li MM, Zhinong Zhang MB, Weihong Song MB, Jingfang Sun MM,Â
doi : 10.1111/dom.14971
To evaluate the efficacy and safety of janagliflozin, a selective renal sodium-glucose cotransporter-2 inhibitor, as monotherapy in drug-naive Chinese patients with type 2 diabetes mellitus (T2DM).
A co-formulation of pramlintide and insulin A21G (ADO09) improves postprandial glucose and short-term control of mean glucose, time in range, and body weight versus insulin aspart in adults with type 1 diabetes
Grit Andersen MD, Rosy Eloy MD, Susanne Famulla PhD, Tim Heise MD, Grégory Meiffren PhD, Cyril Seroussi MSc, Martin Gaudier PhD, Claire Mégret PhD, You-Ping Chan PhD, Olivier Soula PhD, Matthew Riddle MD,Â
doi : 10.1111/dom.14972
Pramlintide improves postprandial glucose but requires additional injections. We investigated the pharmacokinetics/pharmacodynamics, efficacy and safety of ADO09, pramlintide/insulin A21G co-formulation, in type 1 diabetes (T1D).
iGlarLixi versus premixed insulin initiation in adults with type 2 diabetes advancing from basal insulin therapy: The SoliComplex real-world study
Rosemarie Lajara MD, Caroline Heller MPH, Kevin M. Pantalone DO, Elisheva Lew MS, Xuan Li MS, Terry Dex Pharm D, Catherine Rachel Kilpatrick MD,Â
doi : 10.1111/dom.14974
To compare outcomes in adults with type 2 diabetes (T2D) suboptimally controlled with basal insulin who initiated treatment with iGlarLixi or premixed insulin.
Joint longitudinal and time-to-event modelling compared with standard Cox modelling in patients with type 2 diabetes with and without established cardiovascular disease: An analysis of the EXSCEL trial
Abderrahim Oulhaj PhD, Faisal Aziz PhD, Abubaker Suliman MSc, Nayyar Iqbal MD, Ruth L. Coleman PhD, Rury R. Holman MD, Harald Sourij MD,Â
doi : 10.1111/dom.14975
To demonstrate the gain in predictive performance when cardiovascular disease (CVD) risk prediction tools (RPTs) incorporate repeated rather than only single measurements of risk factors.
Effects of sodium-glucose cotransporter 2 inhibitors, mineralocorticoid receptor antagonists, and their combination on albuminuria in diabetic patients
Ryutaro Morita MD, Shunichiro Tsukamoto MD, Shota Obata MD, Takayuki Yamada PhD, Kazushi Uneda PhD, Tatsuki Uehara MD, Muhammad Ebad Rehman MD, Kengo Azushima PhD, Hiromichi Wakui PhD, Kouichi Tamura PhD,Â
doi : 10.1111/dom.14976
Diabetes mellitus (DM) is the leading cause of chronic kidney disease. Albuminuria is associated with an increased risk of cardiovascular mortality. Sodium-glucose cotransporter 2 inhibitors (SGLT2-Is) and mineralocorticoid receptor antagonists (MRAs) protect against albuminuria; however, their combined effects on albuminuria are unclear.
Pyridoxamine reduces methylglyoxal and markers of glycation and endothelial dysfunction, but does not improve insulin sensitivity or vascular function in abdominally obese individuals: A randomized double-blind placebo-controlled trial
Mathias D. G. Van den Eynde MSc, Alfons J. H. M. Houben PhD, Jean L. J. M. Scheijen PhD, Armand M. A. Linkens PhD, Petra M. Niessen PhD, Nynke Simons PhD, Nordin M. J. Hanssen PhD, Yvo H. A. M. Kusters PhD, Simone J. M. P. Eussen PhD, Toshio Miyata PhD, Coen D. A. Stehouwer PhD, Casper G. Schalkwijk PhD,Â
doi : 10.1111/dom.14977
To investigate the effects of pyridoxamine (PM), a B6 vitamer and dicarbonyl scavenger, on glycation and a large panel of metabolic and vascular measurements in a randomized double-blind placebo-controlled trial in abdominally obese individuals.
Long-term cost-effectiveness analysis of tirzepatide versus semaglutide 1.0 mg for the management of type 2 diabetes in the United States
William J. Valentine PhD, Meredith Hoog MPH, Reema Mody PhD, Mark Belger BSc, Richard Pollock MSci,Â
doi : 10.1111/dom.14979
To evaluate the long-term cost-effectiveness of tirzepatide (5, 10 and 15 mg doses), a novel glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, versus semaglutide 1.0 mg, an injectable glucagon-like peptide-1 receptor agonist, based on the results of the head-to-head SURPASS-2 trial, from a US healthcare payer perspective.
Professional continuous glucose monitoring in patients with diabetes mellitus: A systematic review and meta-analysis
Sergio Di Molfetta MD, Irene Caruso MD, Angelo Cignarelli MD, Annalisa Natalicchio MD, Sebastio Perrini MD, Luigi Laviola MD, Francesco Giorgino MD,Â
doi : 10.1111/dom.14981
To evaluate the effect on glucose control of professional continuous glucose monitoring (p-CGM)-based care as compared with standard care in the management of patients with type 1 and type 2 diabetes.
Identifying diabetogenic drugs using real world health care databases: A Danish and Australian symmetry analysis
Lars Christian Lund PhD, Patricia Hjorslev Jensen MD, Anton PottegÃ¥rd DMSc, Morten Andersen PhD, Nicole Pratt PhD, Jesper Hallas DMSc,Â
doi : 10.1111/dom.14982
Drug-induced diabetes is underreported in conventional drug safety monitoring and may contribute to the increasing incidence of type 2 diabetes. Therefore, we used routinely collected prescription data to screen all commonly used drugs for diabetogenic effects.
Effects of co-ingesting glucose and whey protein on blood glucose, plasma insulin and glucagon concentrations, and gastric emptying, in older men with and without type 2 diabetes
Avneet Oberoi MSc, Caroline Giezenaar PhD, Rachael S. Rigda BSc, Michael Horowitz MBBS, Karen L. Jones PhD, Ian Chapman MBBS, Stijn Soenen PhD,Â
doi : 10.1111/dom.14983
To investigate whether co-ingestion of dietary protein with, or before, carbohydrate may be a useful strategy to reduce postprandial hyperglycaemia in older men with type 2 diabetes (T2D).
Therapeutic inertia related to the injectable glucagon-like peptide-1 receptor agonists dulaglutide and semaglutide in patients with type 2 diabetes in UK primary care
Lill-Brith von Arx PhD, Jonathan Rachman MBChB, Joanne Webb MBChB, Caroline Casey PhD, Amisha Patel PhD, Christina Diomatari MSc, Robert Wood BSc, Iskandar Idris Dm,Â
doi : 10.1111/dom.14985
To determine the extent of therapeutic inertia related to the weekly injectable glucagon-like peptide-1 receptor agonists dulaglutide and semaglutide in patients with type 2 diabetes (T2D) in the United Kingdom.
Impact of baseline kidney function on the effects of sodium-glucose co-transporter-2 inhibitors on kidney and heart failure outcomes: A systematic review and meta-analysis of randomized controlled trials
Ernesto Maddaloni MD, Ilaria Cavallari MD, Ylenia La Porta MD, Alessandro Appetecchia MD, Luca D'Onofrio MD, Francesco Grigioni MD, Raffaella Buzzetti MD, Rury R. Holman MD,Â
doi : 10.1111/dom.14986
To determine whether the magnitude of the cardiorenal benefits of sodium-glucose co-transporter-2 inhibitors (SGLT2is) varies with baseline kidney function.
Integrated safety and efficacy analysis of dasiglucagon for the treatment of severe hypoglycaemia in individuals with type 1 diabetes
Simon Heller MD, Tadej Battelino MD, Timothy S. Bailey MD, Thomas R. Pieber MD, Ulrike Hövelmann MD, Leona Plum-Mörschel MD, Anita E. Melgaard MSc, Ronnie Aronson MD, Linda A. DiMeglio MD, Thue Johansen MD, Thomas Danne MD,Â
doi : 10.1111/dom.14987
To perform an integrated analysis of the safety and efficacy of dasiglucagon, a glucagon analogue available in a ready-to-use aqueous formulation, to treat severe hypoglycaemia (SH) in type 1 diabetes (T1D).
Meta-analysis of head-to-head clinical trials comparing incretin-based glucose-lowering medications and basal insulin: An update including recently developed glucagon-like peptide-1 (GLP-1) receptor agonists and the glucose-dependent insulinotropic polypeptide/GLP-1 receptor co-agonist tirzepatide
Michael A. Nauck MD, Abd El Aziz Mirna MD, Daniel R. Quast MD,Â
doi : 10.1111/dom.14988
To assess comparative efficacy, safety and tolerability of injectable incretin-based glucose-lowering medications (IBGLMs) versus basal insulin treatment in patients with type 2 diabetes.
Cardiovascular outcomes trial data from EMPA-REG OUTCOME, CAROLINA and CARMELINA: Assessment of a novel staging system for type 2 diabetes
Moahad S. Dar MD, Christoph Wanner MD, Nikolaus Marx MD, Anne Pernille Ofstad MD, Michaela Mattheus Dipl Biostat, Stefan Kaspers MD, Sami A. Bég MD,Â
doi : 10.1111/dom.14989
To apply the diabetes staging system (DSS), a novel disease staging system similar to what is used in oncology but designed to improve diabetes management, to three large type 2 diabetes (T2D) cardiovascular (CV) outcome trials to assess whether increasing DSS stage was associated with higher rates of all-cause mortality (ACM) and/or CV death.
Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmes
Vanita R. Aroda MD, Umut Erhan MD, Peter Jelnes PhD, Juris J. Meier MD, Morten Tind Abildlund MSc, Richard Pratley MD, Tina Vilsbøll MD, Mansoor Husain MD,
doi : 10.1111/dom.14990
Glucagon-like peptide-1 receptor agonists improve glycaemic control: some are now available as oral and subcutaneous formulations, and some have indications for reducing cardiovascular risk. The expanded scope for these therapies warrants comprehensive safety evaluations. We report the safety/tolerability of subcutaneous and oral semaglutide from the SUSTAIN and PIONEER clinical trial programmes, respectively.
Potential for residual cardiovascular risk reduction: Eligibility for icosapent ethyl in the VERTIS CV population with type 2 diabetes and atherosclerotic cardiovascular disease
Joseph M. Kim MD, Deepak L. Bhatt MD, Samuel Dagogo-Jack MD, David Z. I. Cherney MD, Francesco Cosentino MD, Darren K. McGuire MD, Richard E. Pratley MD, Chih-Chin Liu PhD, Nilo B. Cater MD, Robert Frederich MD, James P. Mancuso PhD, Christopher P. Cannon MD,Â
doi : 10.1111/dom.14965
Beta-cell function in treatment-naïve patients with type 2 diabetes mellitus: Analyses of baseline data from 15 clinical trials
Matthias Blüher MD, Ankur Malhotra MD, Giovanni Bader MD,Â
doi : 10.1111/dom.14969
Patient perspectives and experiences with basal insulin titration in type 2 diabetes in the United States: A cross-sectional survey
Stewart B. Harris MD, Kamel Mohammedi MD, Monica Bertolini MD, John White MS, Valery Walker MSc, Fang Liz Zhou MD, John E. Anderson MD, Jochen Seufert MD,Â
doi : /10.1111/dom.14973
Effects of canagliflozin on liver steatosis and fibrosis markers in patients with type 2 diabetes and chronic kidney disease: A post hoc analysis of the CREDENCE trial
Akihiko Koshino MD, Megumi Oshima PhD, Clare Arnott PhD, Robert A. Fletcher MSc, George L. Bakris MD, Meg Jardine PhD, Kenneth W. Mahaffey MD, Vlado Perkovic PhD, Carol Pollock PhD, Hiddo J. L. Heerspink PhD, Brendon L. Neuen PhD,Â
doi : 10.1111/dom.14978
